ArticleAdvanced materials interfaces2022
Biofunctionalization of Graphene-Based FET Sensors through Heterobifunctional Nanoscaffolds: Technology Validation toward Rapid COVID-19 Diagnostics and Monitoring.
Article in Advanced materials interfaces, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 48 citations in OpenAlex.
- Ultrasensitive Detection of Neurofilament Light in Plasma Using F(Ab')Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Graphene-Based Biosensors: Enabling the Next Generation of Diagnostic Technologies-A Review.Biosensors · 2025Review
- Advanced Materials for Biological Field-Effect Transistors (Bio-FETs) in Precision Healthcare and Biosensing.Advanced healthcare materials · 2025Review
- Ultra-sensitive heterojunction double gate BioTFET device for SARS-CoV-2 biomolecules detection.Scientific reports · 2025Article
- A Planar-Gate Graphene Field-Effect Transistor Integrated Portable Platform for Rapid Detection of Colon Cancer-Derived Exosomes.Biosensors · 2025Article
- Applications of Novel Microscale and Nanoscale Materials for Theranostics: From Design to Clinical Translation.Pharmaceutics · 2024Review
- Digitalization of Enzyme-Linked Immunosorbent Assay with Graphene Field-Effect Transistors (G-ELISA) for Portable Ferritin Determination.Biosensors · 2024Article
- Advances in nanobiosensors during the COVID-19 pandemic and future perspectives for the post-COVID era.Nano convergence · 2024Review
- Nano-biosensor for SARS-CoV-2/COVID-19 detection: methods, mechanism and interface design.RSC advances · 2023Review
- Review on two-dimensional material-based field-effect transistor biosensors: accomplishments, mechanisms, and perspectives.Journal of nanobiotechnology · 2023Review
- PEDOT-Polyamine-Based Organic Electrochemical Transistors for Monitoring Protein Binding.Biosensors · 2023Article
- Biosensors based detection of novel biomarkers associated with COVID-19: Current progress and future promise.Biosensors & bioelectronics: X · 2022Review
- Biofunctionalization of Graphene-Based FET Sensors through Heterobifunctional Nanoscaffolds: Technology Validation toward Rapid COVID-19 Diagnostics and Monitoring.Advanced materials interfaces · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biofunctionalization of graphene field-effect transistors (GFETs) through vinylsulfonated-polyethyleneimine nanoscaffold is presented for enhanced biosensing of severe acute respiratory-related coronavirus 2 (SARS-CoV-2) spike protein and human ferritin, two targets of great importance for the rapid diagnostic and monitoring of individuals with COVID-19. The heterobifunctional nanoscaffold enables covalent immobilization of binding proteins and antifouling polymers while the whole architecture is attached to graphene by multivalent π-π interactions. First, to optimize the sensing platform, concanavalin A is employed for glycoprotein detection. Then, monoclonal antibodies specific against SARS-CoV-2 spike protein and human ferritin are anchored, yielding biosensors with limit of detections of 0.74 and 0.23 nm, and apparent affinity constants (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.